Lipid nanoparticle-mediated in vivo generation of panCAR immune cells for solid tumor immunotherapy - PubMed
3 days ago
- #immunotherapy
- #lipid nanoparticles
- #solid tumors
- Lipid nanoparticles (LNPs) enable in vivo generation of panCAR immune cells for solid tumor immunotherapy.
- The LNP platform allows systemic delivery of CAR-encoding mRNA, engineering T cells, macrophages, dendritic cells, and NK cells across multiple tissues.
- Repeated administration of LNP-panCARHER2 inhibits tumor growth and prolongs survival in murine models without significant side effects.
- The therapy remodels the tumor microenvironment to an immunostimulatory phenotype, reducing M2-like macrophages and increasing effector T cells.
- This approach offers an off-the-shelf, in vivo CAR cell therapy platform for solid tumors.